SEC Comment Letter 0000000000-22-013778 to Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc.
Date: Dec. 21, 2022 · CIK: 0001540159 · Accession: 0000000000-22-013778
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268847
Letter
United States securities and exchange commission logo December 21, 2022 Kathi Niffenegger Chief Financial Officer Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 Re:Edesa Biotech, Inc. Registration Statement on Form S-3 Filed December 16, 2022 File No. 333-268847 Dear Kathi Niffenegger : This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tracy Buffer
Show Raw Text
United States securities and exchange commission logo
December 21, 2022
Kathi Niffenegger
Chief Financial Officer
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
Re:Edesa Biotech, Inc.
Registration Statement on Form S-3
Filed December 16, 2022
File No. 333-268847
Dear Kathi Niffenegger :
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Tracy Buffer